XT
STRO icon

XTX Topco’s Sutro Biopharma STRO Stock Holding History

XTX Topco’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Buy
+8,203
New +$148K ﹤0.01% 2832
2025
Q4 		– Sell
-1,913
Closed -$16.6K – 3778
2025
Q3 		$16.6K Buy
+1,913
New +$16.3K ﹤0.01% 2362
2025
Q2 		– Sell
-2,517
Closed -$16.4K – 3133
2025
Q1 		$16.4K Buy
2,517
+336
+15% +$5.29K ﹤0.01% 2182
2024
Q4 		$40.1K Sell
2,181
-8,239
-79% -$252K ﹤0.01% 1934
2024
Q3 		$361K Buy
10,420
+7,184
+222% +$282K 0.03% 1070
2024
Q2 		$94.8K Sell
3,236
-5,654
-64% -$224K 0.01% 1428
2024
Q1 		$502K Buy
8,890
+591
+7% +$26.1K 0.07% 486
2023
Q4 		$356K Buy
8,299
+6,254
+306% +$198K 0.08% 491
2023
Q3 		$70.9K Buy
+2,045
New +$89.1K 0.01% 1229
2023
Q2 		– Sell
-10,078
Closed -$466K – 1819
2023
Q1 		$466K Sell
10,078
-59
-0.6% -$3.74K 0.1% 336
2022
Q4 		$819K Buy
10,137
+4,375
+76% +$304K 0.17% 131
2022
Q3 		$320K Buy
5,762
+2,244
+64% +$133K 0.08% 463
2022
Q2 		$183K Buy
+3,518
New +$197K 0.07% 488

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

XTX Topco's STRO Position: Q1 2026 in Review

XTX Topco opened a new position in Sutro Biopharma (STRO) in Q1 2026: 8,203 shares worth $204K. The stake represents ﹤0.01% of the portfolio and ranks #2832 among its holdings. This is a return to the name: XTX Topco previously reported a position in STRO as recently as Q3 2025.

XTX Topco first reported a position in STRO in Q2 2022 and has held it in 13 quarters since. The position peaked at $819K in Q4 2022. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • XTX Topco held 8,203 shares of Sutro Biopharma worth $204K as of Q1 2026.
  • Sutro Biopharma was a new XTX Topco position in Q1 2026.
  • Sutro Biopharma made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #2832 holding.
  • XTX Topco first reported a position in Sutro Biopharma in Q2 2022 and has held it in 13 quarters since.
  • XTX Topco's Sutro Biopharma position peaked at $819K in Q4 2022.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.